The global resurgence of coronavirus 2 (SARS-CoV-2) has severely affected the medical infrastructure, posing a serious public health concern. The present case series documents the successful management of four moderate cases of confirmed coronavirus disease (COVID-19) based on the Ayurveda approach without any adverse effects and any post-COVID presentation. A retrospective analysis of four patients with moderate COVID-19 symptoms was conducted in this study at the All India Institute of Ayurveda. The patients were between the age of 23 and 38 years, were diagnosed as COVID-19 positive through a rapid antigen test (RAT), in July–August 2020, and were managed through Ayurveda interventions. The interventions include Ayush Kwath (10 g twice a day) and Sanshamani Vati (500 mg thrice a day) along with dietary restrictions and nonpharmacological suggestions. The therapeutic interventions were carried out for 7 days. Symptomatic assessment was done every day telephonically, and RAT was conducted after 7 days. Post-COVID complications were assessed in individual cases during the follow-up period (3 months after the completion of treatment). Complete relief in symptoms was observed within 6–7 days in all the cases. No side effects or adverse drug reactions were noticed both during and after the treatment. No post-COVID complications were observed in the four studied cases. The case series suggests that timely Ayurveda intervention has very good potential not only in treating mild-to-moderate patients of COVID-19 infection but also in preventing the post-COVID complications. It could also have a role in reducing the burden of a patient’s turning into a severe category or with complications. However, large-scale randomized controlled trials are required to further validate the same.

Ayurveda, a traditional Indian healing system, offers a holistic approach to mental health by addressing mind, body, and spirit imbalances, unlike conventional psychiatry’s symptom-focused treatments. This narrative review evaluates the efficacy and integrative potential of Ayurvedic interventions for disorders like anxiety, depression, schizophrenia, and insomnia. A literature searches up to April 2025 across PubMed, Google Scholar, DOAJ, DHARA, and AYUSH Research Portal, using terms like "mental health" and "Ayurveda," or "Panchakarma" yielded initial 394 articles. After deduplication, removal of review articles, and screening of titles/abstracts, irrelevant records, 54 freely available full text articles were selected, of which 22 peer-reviewed studies (clinical trials, case reports) on interventions like Detoxification therapy (Panchakarma), Cognitive Rejuvenator (Medhya Rasayanas), and Psychocognitive behavioral therapy (Satvavajaya Chikitsa) were included for review, supplemented by Charak Samhita and reference lists. Data on study, interventions, and outcomes were extracted. Narrative synthesis revealed significant symptom relief in schizophrenia (Brahmyadi Yoga, Smriti Sagara Rasa), depression (Shirodhara, Virechana), and anxiety (Ashwagandha, Yoga), with case reports showing enhanced quality of life and reduced medication dependency when integrated with conventional therapies. Combining Ayurveda’s holistic focus with modern psychiatry amplifies patient-centered outcomes, yet regulatory inconsistencies and limited large-scale trials hinder broader adoption. Ayurveda presents a complementary strategy, particularly in resource-scarce settings, but requires robust trials and standardized protocols to bridge evidential gaps and enhance global mental health integration.

Background: Cancer poses a major global health challenge, with rising incidence and mortality rates straining healthcare systems worldwide. Despite remarkable advances in cancer management modalities, the current approaches still fall short in overcoming drug resistance, tumour heterogeneity, toxicity and side effects. Traditional systems such as Ayurveda and Siddha may help overcome these limitations of conventional medicine; however, robust evidence supporting the anticancer efficacy of Herbo mineral formulations (HMFs) remains limited and fragmented. Objective: This scoping review is planned to map the existing pre-clinical evidence from in vitro and in vivo studies for the anticancer activities of Ayurveda and Siddha HMFs. Methods: The scoping review will be conducted in accordance with the framework proposed by Arksey and O’Malley and the recommendations of the Joanna Briggs Institute for conducting scoping reviews. A systematic search will be conducted by two independent reviewers across selected databases for relevant literature, and studies will be selected on the basis of predefined eligibility criteria. Data from the included studies will be presented in tabular and narrative formats to align with the review objectives. The review will be reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews guidelines. Discussion: This review will contribute to integrating traditional medicine with modern oncology, guiding researchers and clinicians in prioritizing promising anticancer drugs for further investigation and potential therapeutic use. The review protocol was registered with the Open Science Framework (OSF) and is available at: osf.io/rdhpv/.